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Abstract  61 
Background: Epidermal hyperplasia represents a morphologic hallmark of psoriatic skin lesions. 62 
Langerhans cells (LCs) in the psoriatic epidermis engage with keratinocytes (KCs) in tight physical 63 
interactions; moreover, they induce T cell-mediated immune responses critical to psoriasis.  64 
Objective: Epidermal factors in psoriasis pathogenesis remain poorly understood.   65 
Methods: We phenotypically characterized BMP7-LCs vs. TGF-β1-LCs and analyzed their functional 66 
properties using flow cytometry, cell kinetic studies, co-culture with CD4 T-cells and cytokine 67 
measurements. Furthermore, immunohistology of healty and psoriatic skin was performed.  68 
Additionally, in vivo experiments with Junf/fJunBf/fK5creER mice were carried out to assess the role of 69 
BMP signaling in psoriatic skin inflammation. 70 
Results: Here we identified a KC-derived signal, i.e. bone morphogenetic protein (BMP) signaling, to 71 
promote epidermal changes in psoriasis. Whereas BMP7 is strictly confined to the basal KC layer in 72 
the healthy skin, it is expressed at high levels throughout the lesional psoriatic epidermis. BMP7 73 
instructs precursor cells to differentiate into LCs that phenotypically resemble psoriatic LCs. These 74 
BMP7-LCs exhibit proliferative activity and increased sensitivity to bacterial stimulation. Moreover, 75 
aberrant high BMP signaling in the lesional epidermis is mediated by a KC intrinsic mechanism, as 76 
suggested from murine data and clinical outcome aftr topical anti-psoriatic treatment in human 77 
patients.  78 
Conclusion: Our data indicate that available TGF-β family members within the lesional psoriatic 79 
epidermis preferentially signal through the canonical BMP signaling cascade to instruct inflammatory-80 
type LCs and to promote psoriatic epidermal changes. Targeting BMP signaling might allow to 81 









Introduction  89 
Langerhans cells (LCs) are a subset of dendritic cells (DCs) populating the epidermis and other 90 
squamous epithelia (1). They protect keratinocytes (KCs) from UV light-induced apoptosis (2) and 91 
contribute to skin homeostasis by maintaining proliferation of skin resident regulatory T cells (Tregs) 92 
(3,4). Psoriatic lesions are marked by epidermal thickening (acanthosis) due to impaired differentiation 93 
and enhanced proliferation of KCs (5).  The human lesional psoriatic epidermis harbors two subsets of 94 
DCs: LCs and epithelial dendritic cells (DCs) that exhibit certain LC characteristics (6). These 95 
epidermal DCs are in physical contact with KCs and therefore might play critical roles in psoriasis-96 
associated epidermal changes, as suggested from murine studies (7,8). Vice versa, psoriatic KCs might 97 
instruct precursors to adopt a disease-associated LC phenotype. Nevertheless, the functional roles of 98 
epidermal DCs and LCs remain poorly characterized as most published studies focused on dermal DCs 99 
(9). Following an inflammatory insult, endogenous LCs egress from the epidermis and are 100 
subsequently replenished from circulating monocytes (10–13), which acquire LC characteristics, but 101 
retain certain monocyte features (11). They seem to disappear after the resolution of inflammation and102 
are subsequently replaced by proliferation of residual local LCs (14) or by immigrating non-monocyte, 103 
bone marrow-derived precursors (15). The epidermal microenvironment plays a key role in instructing 104 
LC differentiation (16), as highlighted by the observations that subsets of LCs from oral mucosa vs 105 
epidermis arise from distinct precursors; nevertheless, they exhibit a similar gene expression profile 106 
(17). In vitro studies revealed that besides monocytes, also human blood CD1c+ DCs and CD14+ 107 
dermal cells can differentiate into LCs (18–20). In vitro, keratinocyte-derived factors such as TGF-β1 108 
and BMP7 in cooperation with thymic stromal lymphopoietin (TSLP) and Notch ligands promote in 109 
vitro LC differentiation from human monocytes or monocyte-committed intermediates (21–23). 110 
However, unlike monocytes, CD1c+ blood DCs do not require exogenous Notch ligand for LC 111 
differentiation (19). Belonging to the TGF-β family, TGF-β1 and BMP7 both signal via BMP type-I 112 
receptor ALK3 to induce LC differentiation i vitro (24), and TGF-β1 can be replaced by BMP7 for 113 
instructing LC differentiation from CD1c+ blood DCs and hematopoietic progenitor cells (19). 114 
Conversely, deletion of either TGF-β1, TGF-β1RII (25–27) or TGF-β type I receptor ALK5 (28,29) in 115 
differentiated CD207+ cells results in their emigration from the epidermis to the lymph nodes shortly 116 
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after birth. Moreover, ALK5 is dispensable for human LC differentiation in vitro (24). Whether or 117 
how local expression of TGF-β ligands in the healthy and diseased epidermal microenvironment affect 118 
LC phenotype and function remains poorly understood. Considering the suspected functional 119 
importance of LCs in the maintenance of epidermal homeostasis, a better characterization of TGF-β 120 
family signaling in the psoriatic epidermis is of considerable medical relevance. Therefore, we here 121 
asked: What are the phenotypic and functional charate istics of BMP7-instructed LCs, and can we 122 
find such cells in vivo under pathophysiological conditions? We here identifi d BMP signaling to be 123 
functionally involved in the progression of psoriatic epidermal thickening, and to serve as an 124 





















Materials and Methods 144 
In vitro generation of CD34+ progenitor cell-derived LCs, CD14+ monocyte-derived DCs 145 
(moDCs) and LCs (moLCs), and CD1c+ blood DCs-derived LCs (CD1c-LCs).    146 
CD34+ cord blood HSCs were expanded for 3 days in serum-fee X-vivoTM15 medium (Lonza, 147 
Switzerland) supplemented with: 50ng/ml SCF, FLT3-L, TPO each. In vitro LCs were generated as 148 
previously described (30). In brief, expanded CD34+ cells (4x104/ml) were cultured for 7 days in 149 
serum-free CellGenix® GMP DC medium (CellGenix, Germany) supplemented with: 100ng/ml GM-150 
CSF, 50ng/ml FLT3-L, 20ng/ml SCF, 2.5ng/ml TNFα, and 1ng/ml TGF-β1 or 200ng/ml BMP7. For 151 
moDC generation, CD14+ monocytes (1x106/ml) were cultured for 6 days in RPMI-1640 + 10% FBS 152 
(Sigma-Aldrich, USA) supplemented with: 35ng/ml IL-4 and 100ng/ml GM-CSF. For CD1c-LC 153 
generation, peripheral blood CD1c+DCs (5x105/ml) were cultured for 3-4 days in RPMI-1640 + 10% 154 
FBS supplemented with: 100ng/ml GM-CSF, and 10ng/ml TGF-β1 or 200ng/ml BMP7. For moLC 155 
generation, CD14+ monocytes (1x106/ml) were cultured for 5 days in Delta-1 coated plates (31) in 156 
RPMI-1640 + 10% FBS supplemented with: 100ng/ml GM-CSF, and 10ng/ml TGF-β1 or 200ng/ml 157 
BMP7. 158 
Flow cytometry  159 
Flow cytometry staining (extracellular epitopes) was performed as previously described (32). Data 160 
were acquired with LSRII instrument (BD Bioscience, USA) and analyzed with FlowJo software (Tree 161 
Star, Inc. USA). For the FACS sorting the BD FACS Aria flow cytometer (BD Bioscience, USA) was 162 
used. Monoclonal antibodies are listed in the supplementary table 1. 163 
Cytokine measurements  164 
Day 7 CD207+LCs were MACS sorted (purity ≥90%) and activated with 5µg/ml PGN. After 48h 165 
supernatants were collected. The proteome profiler human cytokine array kit (R&D Systems, USA) 166 
was used according to the manufacturer’s instructions. Spot intensity was quantified with ImageLabTM 167 
software (BioRad). For the quantitative measurement of cytokines in the supernatants from MLRs 168 




Dithranol clinical trial 171 
Paraffin-embedded materials from pre- and post-tream nt (4 weeks after therapy completion) biopsy 172 
samples were available from six patients (5 men, 1 woman; age range 21-77 years) of a clinical study 173 
investigating the effect of topical dithranol in psoriasis. Dithranol study Clinical Trials.gov  174 
no.NCT02752672; approval number A23/15, Ethical Committee of the State of Carinthia, Austria.  175 
Statistics 176 
Statistical analysis was performed using 2-tailed t-test or one-way ANOVA (corrected with Tukey 177 
multiple comparison test) with GraphPad Prism6 software (GraphPad Software Inc.). p-values ≤0.05 178 
were considered significant.  179 
 180 
Detailed description of cytokines and reagents, cell iso ation, preparation of single cell suspension 181 
from psoriatic skin biopsies, RNA isolation and gene expression analysis, cytokine measurements, 182 
transmission electron microscopy, immunofluorescence and immunohistochemistry, mice, intradermal 183 
noggin injections in mice, dorsomorphin treatment, murine skin thickness measurement, and T-cell 184 














BMP7-LCs are responsive to TLR2 stimulation 197 
We recently found that BMP7 replaces TGF-β1 in instructing LC differentiation from CD34+ 198 
hematopoietic progenitor cells (24). Adding either TGF-β1 or BMP7 to a mix of cytokines in serum-199 
free medium promotes the formation of E-cadherin-mediat d clustering CD1a+CD207+ LCs (Fig. 1A). 200 
TGF-β1- and BMP7-generated LCs (termed TGF-β1-LCs and BMP7-LCs, respectively) both exhibit 201 
phenotypic characteristics of LCs (CD1a+CD207+CD324+ (24)). However, genome-wide microarray 202 
analyses of sorted CD1a+CD207+ cells revealed several differentially expressed genes in BMP7-LCs 203 
vs. TGF-β1-LCs (Fig. 1B). Subsequent qRT-PCR analyses showed that both TGF-β1-LCs and BMP7-204 
LCs lack detectable expression of several toll-like receptors (i.e. TLRs 3, 4, 5, 7, 8, 9), as also 205 
observed for ex vivo isolated LCs (33). However, BMP7-LCs express higher levels of bacterial 206 
recognition receptor TLR2 (Fig. 1C, 1D) and lower lvels of TLR1, TLR6, as well as lower levels of 207 
anti-inflammatory TLR10 (34,35) than TGF-β1-LCs (Fig. 1C). Moreover, TLR2 positivity by BMP7-208 
LCs is correlated with reduced CD207 expression (Fig. 1D). Bacterial ligand peptidoglycan (PGN) 209 
was added to TGF-β1-LCs vs. BMP7-LCs to analyze their cytokine/chemokine response to TLR2-210 
mediated stimulation (Fig. 1E). Analyzing a limited panel of cytokines, we previously found that 211 
BMP7-LCs indeed exceed TGF-β1-LCs in PGN-induced cytokine production (24). We here confirmed 212 
and extended on these observations. BMP7-LCs responded to PGN with increased synthesis of several 213 
cytokines (i.e. TNFα, IL6, and GM-CSF) and chemokines (CXCL1, CCL3/4, and CCL1) relative to 214 
TGF-β1-LCs (Fig. 1E). Moreover, TGF-β1-LCs equaled BMP7-LCs in their basal and PGN-induce  215 
production of IL-8, IL-21, CCL2, ICAM1 and CCL5 (Fig. 1E). To further investigate functional 216 
aspects of BMP7-LCs, we performed a mixed lymphocyte reaction (MLR). This analysis showed that 217 
BMP7-LCs are not only more potent stimulators of T cell proliferation than TGF-β1-LCs (Fig. S1A), 218 
but they also primed naive CD4 T cells towards high production of GM-CSF, TNFα, IL-1β, and IL-2. 219 
Inversely, TGF-β1-LCs stimulated CD4 T cells to secrete high levels of anti-inflammatory IL-10 (Fig. 220 




BMP7 promotes the generation of LCs exhibiting CD1c+CD206+ phenotype 223 
Above-mentioned gene array profiling (Fig. 1B) revealed differential expression of several mRNAs 224 
encoding cell surface molecules. Subsequent flow cytometry showed that BMP7-LCs express higher 225 
levels of CD11c, CD1c, CD206, CD36, CD80, CXCR1 and CX3CR1, and lower levels of Trop2 226 
(TACSTD2) than TGF-β1-LCs (Fig. 2A). Therefore, BMP7-LCs differ from both in vitro generated 227 
TGF-β1-LCs and ex vivo isolated LCs in that they are CD1chiCD206hiCD36hiTROP2lo/neg. Moreover, 228 
BMP7-LCs exhibit constitutively active canonical BMP signaling, as evidenced by their significantly 229 
higher expression level of pSmad1/5/8, when compared to TGF-β1-LCs (Fig. S2). Given their 230 
inflammation-associated characteristics (Fig.1, Fig. S1), we phenotypically compared BMP7-LCs to 231 
monocyte-derived DCs (moDCs) known to resemble inflammatory dendritic epidermal cells (IDECs) 232 
in eczema/atopic dermatitis lesions (36–39). BMP7-LCs clearly differed from moDCs in parallel 233 
analyses (compare Fig. S3 with Fig. 2A). First, moDCs lack LC-associated CD207, CD324/E-234 
cadherin, EpCAM and TACSTD2/TROP2; Second, unlike BMP7-LCs, moDCs express high levels of 235 
CD209/DC-SIGN and CD11b (Fig. S3 (40,41)). 236 
 237 
LCs generated from peripheral blood precursors are CD206+CD1c+ 238 
Murine studies showed that during inflammation LCs develop from monocytes (10,11,13). Recently, 239 
human CD1c+ blood DCs were identified as candidate LC precursors, since they rapidly (within 72h) 240 
differentiate into CD207+CD1a+LCs (19). Whether LCs generated from these cells phenotypically 241 
resemble inflammation-associated LCs remains unknown. We purified CD1c+ blood DCs from MNCs 242 
by first depleting monocytes and B cells, followed by anti-CD1c positive selection. Importantly, 243 
CD1c+ blood DCs were resolved as a distinct population from CD14+ monocytes (Fig. 2B). Both 244 
CD1c+ blood DCs and CD14+ monocytes differentiated into CD206+CD1c+CD36+CD207+CD1a+LCs 245 
in both TGF-β1/GM-CSF and BMP7/GM-CSF cultures (Fig. 2C, 2D). Therefore, LCs generated from 246 
CD14+ monocytes or CD1c+ blood DCs exhibit a CD206+CD1c+ phenotype, irrespective of whether 247 





BMP7-LCs lack detectable Birbeck granules 251 
Birbeck granules (BG) represent a hallmark ultrastructural characteristic of LCs. It was previously 252 
shown that a subset of lesional psoriatic epidermal LCs lack detectable BG (37). Moreover, LC 253 
maturation has been associated with depletion of BG, due to reduction of the intracellular langerin 254 
pool (42). Duplicating previous findings (30,43), TGF-β1-LCs contained numerous intracytoplasmic 255 
BG. Conversely, BMP7-LCs lacked BG, despite positivity for CD207.  256 
 257 
BMP7-LCs resemble psoriatic LCs and the psoriatic epidermis is marked by BMP7 induction 258 
CD207+ cells from healthy skin are CD1clow/-CD206neg. Conversely, the psoriatic epidermis harbors 259 
CD207+ cells with phenotypical resemblance to BMP7-LCs as they are also CD1c+CD206+ (Fig. 3A, 260 
3B). Flow cytometry analysis of cells from lesional biopsies confirmed that CD207+ cells found in 261 
psoriatic skin co-express CD1c, CD206 and TLR2, similar to BMP7-LCs (Fig. 3C). We also detected 262 
dermal CD206+CD1c+ cells; however these cells lack CD207 (Fig. 3B). BMP receptors and 263 
downstream effectors can be analyzed in situ. BMPs bind to the type-II receptor (BMPRII), leading to 264 
the recruitment and phosphorylation of a BMP type-I r ceptor and downstream Smad1/5/8. Strikingly, 265 
CD207+LCs in healthy and psoriatic skin are marked by a strong BMPRII expression (Fig. 3D, 3E). 266 
As described previously by our group (24), BMP7 expr ssion is confined to the basal/germinal 267 
keratinocyte layers, a predominant site of LC residncy in healthy human skin (Fig. 4A). In marked 268 
contrast, BMP7 is expressed throughout the acanthotic epidermis, and LCs occur scattered in psoriatic 269 
lesions (Fig. 4B). Whereas the healthy epidermis exhibits a weak phospho-Smad1/5/8 staining pattern 270 
(Fig. 4C), psoriatic LCs and KCs show a strong nuclear accumulation of phospho-Smad1/5/8 (Fig. 271 
4D). JunB is a known psoriasis risk associated gene located on the PSOR6 locus, and JunB expression 272 
is downregulated in psoriatic lesional skin (44). Conversely c-Jun expression is enhanced in the basal273 
layer potentially regulating keratinocyte proliferation (45). Tamoxifen (Tx)-induced, epidermal 274 
deletion of Jun/JunB in the Junf/fJunBf/f K5cre-ERT mouse model causes a psoriasis-like disease (44), 275 
marked by strong lesional epidermal BMP7/phospho-Smad1/5/8 expression (Fig. 4E), duplicating 276 
findings in human. Thus, a genetic defect induced in adult KCs (i.e. Jun/JunB deletion) drives psoriatic 277 
lesion formation (44) associated with high BMP7 expr ssion. Injection of the BMP antagonist noggin 278 
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(nog) is an established in vivo experimental approach to study the importance of BMP signaling in 279 
skin biology (46–49). Thus, we injected intradermally beads-adsorbed nog (nog) into the ears of 280 
Junf/fJunBf/f K5cre-ERT mice 24 h prior to Jun/JunB deletion, and monitored ear swelling for 12 281 
consecutive days (Fig. 4F). Expectedly, as a result of noggin treatment we found diminished 282 
pSmad1/5/8 staining intensity in the epidermis (Fig. S4A). While control mice exhibited progressive 283 
ear thickening from days 5 onwards, nog injected mice showed significantly reduced ear swelling over 284 
the course of the experiment (Fig. 4G, 4H). Histological analysis confirmed decreased epidermal 285 
thickening in nog-injected compared to control-injected animals (Fig. 4I, 4J). Furthermore, treatment 286 
of developed lesions with topical application of the BMP pathway inhibitor dorsomorphin (targeting 287 
type 1 receptors Alk2, 3 and 6) resulted in decreased ear swelling in comparison to the control treated 288 
mice (Fig. S4B). In aggregate, these murine and human data demonstrate that the lesional psoriatic 289 
epidermis is characterized by aberrant high BMP7/phos o-Smad1/5/8 expression, and that BMP7-290 
LCs phenotypically resemble lesional LCs (CD207+CD206+CD1c+). 291 
 292 
BMP7 supplementation is associated with proliferation of CD207+ LCs 293 
LC numbers gradually increase during skin development, and CD207+LCs undergo self 294 
-renewal in vivo (14). However, the epidermal factors promoting LC proliferation remain unknown.  295 
Interestingly, BMP7-supplemented cultures showed vigorous proliferation, increased total cellularity 296 
and elevated numbers of LCs, relative to TGF-β1-supplemented cultures (Fig. 5A, 5B); We detected 297 
mitotic Ki67+ cells among CD207+LCs, with percentages Ki67+ cells being much higher for BMP7-298 
LC than for TGF-β-LCs (Fig. 5C, 5D). Therefore, BMP7 signaling allows active cycling of in vitro 299 
generated LCs. In the healthy adult epidermis, BMP7 expression is confined to basal KCs (Fig. 4A; 300 
5E, left; (24)). We analysed whether Ki67+LCs, known to occur in the healthy epidermis (14), co-301 
localize with BMP7+KCs in situ. Indeed, Ki67+LCs and Ki67+KCs are confined to the BMP7+ 302 
epidermal layers (Fig. 5E, left, 5G). In comparison, higher numbers of Ki67+CD207+LCs and 303 
Ki67+KC are observed in the lesional BMP7hi psoriatic epidermis (Fig. 5E right, 5F). In inflamed skin 304 
the confinement of proliferating cells to the basal epidermal layer was lost, and proliferating LCs and 305 
KCs could be found throughout the enlarged BMP7hi epidermis (Fig. 5E, right; model in Fig. S5).  306 
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Canonical TGF-β1-ALK5 signaling inhibits phenotypic characteristics of BMP7-LCs 307 
In healthy human epidermis, TGF-β1 is expressed in supra-basal/outer KC layers; conversely, BMP7 308 
is confined to basal KCs (Fig. 4A; 5E (24)). Canonical TGF-β1-ALK5 signaling is required to retain 309 
LCs in a non-activated state in situ (27). TGF-β1 co-activates both ALK5 and ALK3 (Fig. 6A), the 310 
latter being required for TGF-β1-dependent LC differentiation i vitro (24); conversely, BMP7 signals 311 
through ALK3 but not ALK5 (Fig. 6A; (24,50,51)). BMP7-LCs and lesional psoriatic LCs are 312 
CD1c+/CD206+, whereas TGF-β1-LCs and steady-state LCs lack these markers (Fig.2A, 3A). We 313 
therefore investigated whether active ALK5 signaling represses CD1c and CD206. Indeed, short-term 314 
(48 h) stimulation of BMP7-LCs with TGF-β1 downregulated both CD1c and CD206 (Fig. 6B, lower 315 
panel). We performed an inversed experiment to validate these findings. Pharmacological inhibition of 316 
the ALK5 receptor in TGF-β1-LC cultures dose-dependently led to the re-establi hment of the 317 
CD1c+CD206+ LC phenotype (Fig. 6C). Together these data reveald that selective ALK3 activation 318 
by BMP7 induces a CD1c+CD206+ LC phenotype, whereas co-activation of the canonical TGF-β1-319 
ALK5 cascade represses CD1c and CD206. 320 
 321 
Topical treatment of psoriatic lesions diminishes BMP7 expression 322 
Topical treatment of psoriatic lesions with dithranol (anthralin) inhibits KC proliferation (52), and our 323 
murine data indicate a KC-intrinsic mechanism of BMP7 induction during the onset of psoriatic-like 324 
epidermal hyperplasia (Fig. 4E). We monitored BMP7 expression in serial lesional skin biopsies 325 
before and after dithranol treatment of psoriatic patients (n=6). Expectedly, before treatment BMP7 326 
was expressed throughout the lesional epidermis (Fig 7A). Four weeks after treatment initiation, 327 
BMP7 staining intensity was markedly reduced with only basal KC layers staining positive for BMP7 328 
(Fig. 7A), similarly as observed in the healthy skin (Fig. 4A). The clinical status of the patients was 329 
monitored using the psoriasis area and severity index (PASI) score. Out of six analysed patients, after 330 
treatment, four exhibited a substantial reduction in BMP7 staining intensity. (Fig. 7A, diagram). 331 
Correlation analysis revealed a positive correlation between BMP7 reduction and PASI score 332 
reduction (Fig. 7B). All four patients with strong BMP7 reduction also had strong reduction in PASI 333 
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score. Conversely, the patient who had no BMP7 decrease also had no PASI score improvement after 334 































Cutaneous psoriatic lesions are characterized by epidermal hyperplasia and are populated by 364 
bone marrow-derived epidermal LC-like cells (6,53). However, the epidermal factors instructing LC 365 
differentiation under normal and diseased conditions are poorly defined. While we previously showed 366 
that BMP7 is confined to the basal KC layer in the healthy epidermis (24), we here demonstrated that 367 
BMP7 and associated downstream BMP signaling components (i.e. phospho-SMAD1/5/8) are highly 368 
expressed throughout the enlarged psoriatic epiderms. Using gene profiling, we further showed that 369 
BMP7 induces the generation of CD1c+CD206+LCs in vitro, phenotypically mimicking psoriasis-370 
associated LC-like cells. Moreover, a substantial fr ction of in vitro generated BMP7-LCs exhibited 371 
mitotic activity, similarly as observed for psoriatic LCs in situ. We previously showed that ~40% of 372 
CD207+LCs in murine psoriatic lesions are of bone marrow origin, and these cells exceeded host-373 
derived LCs in mitotic activity (7). Extending on these analyses we here showed that induction of 374 
psoriatic lesions by genetic targeting of adult KCs in Junf/fJunBf/f K5cre-ERT mice also causes a 375 
BMP7hi/phospho-SMAD1/5/8hi phenotype, indicating a KC-intrinsic mechanism for BMP7 induction. 376 
Together these data suggest a key role for epidermal KC-derived BMP7 in instructing LC 377 
differentiation from bone marrow-derived precursors in psoriatic lesions (see hypothetical model in 378 
Fig. S5). Furthermore, we demonstrated that lesional BMP7 is strongly diminished upon dithranol 379 
treatment of psoriatic patients, and that epidermal BMP7 reduction correlates with clinical 380 
improvement. Moreover, injection of BMP antagonist noggin in Junf/fJunBf/f K5cre-ERT mice led to 381 
the reduction in epidermal thickening, indicating involvement of BMP signaling in psoriatic lesion 382 
formation.  383 
Our phospho-Smad1/5/8 stainings support that the BMP pathway is aberrantly activated in the 384 
psoriatic epidermis. However, despite high expression of BMP7 protein throughout the lesional KCs, 385 
BMP7 might not be the only BMP family member expressed in the psoriatic epidermis. Interestingly, 386 
psoriatic epidermal lesions were previously shown to exhibit diminished canonical TGF-β signaling, 387 
as evidenced by decreased levels of TGF-β type-I receptor ALK5, TGF-βR type-II and phospho-388 
SMAD2/3 (54,55). Moreover, TGF-β2 and TGF-β3 (54,56) are downregulated and inhibitory SMAD7 389 
is induced in the psoriatic epidermis (57). We here showed that the inhibition of ALK5 signaling 390 
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(canonical TGF-β1 signaling) in TGF-β1-LC cultures results in the generation of CD1chiCD206hi LCs 391 
(mimicking lesional LCs). Inversely, adding TGF-β1 to BMP7-LC cultures led to the repression of 392 
CD1c and CD206. In line with impairment of canonical TGF-β1 signaling in inflammation, Bobr et. 393 
al. demonstrated that a portion of murine LCs stain positive for phospho-SMAD2/3 (downstream of 394 
TGF-β1-ALK5) in normal but not in inflamed skin (27).  395 
A side-by-side comparison revealed that BMP7-supplemented LC cultures give rise to much 396 
higher numbers of human LCs compared to TGF-β1-supplemented cultures. Our data suggest a 397 
sequential protocol for the generation of high numbers of LCs from human progenitor cells (i.e. BMP7 398 
followed by TGF-β1) in defined serum-free media for cell therapy-oriented studies. We showed that 399 
high percentages of in vitro generated CD207+BMP7-LCs are Ki67+, indicating that BMP7-ALK3 400 
signaling facilitates LC cycling. In line with this, the type-II BMP receptor BMPR2 is strongly 401 
expressed by LCs in situ, and marks LCs in epidermal immunohistology. Consistent with a role of 402 
BMP7 in facilitating LC cycling, we observed that Ki67+LCs, known to reside in the healthy 403 
epidermis (14,58), are confined to the BMP7+KC layers. Moreover, Ki-67+LCs occurred abundantly 404 
and spatially scattered throughout the BMP7hi human psoriatic epidermis. Since lesional psoriatic LCs 405 
undergo physical clustering with T cells (9), BMP7 might be critically involved in this process.  406 
During ontogeny LC precursors within the epidermal niche are first exposed to BMP7 407 
followed by TGF-β1 (24,59). TGF-β1-ALK5 signaling enables LCs to remain in their non-activated 408 
state, a model directly supported by murine ALK5 (29) and TGF-βRII (26) knock-out studies. 409 
Moreover, sequential BMP7/TGF-β1 signaling was shown to instruct murine mucosal LCs 410 
differentiation (60); reviewed in: (61). Notably, supernatants of cultured keratinocytes (pre-stimulated 411 
or not with IL-17 and TNFα) failed to replace exogenous BMP7 for the promotion f LC 412 
differentiation from CD34+ cells (unpublished observation). Therefore, cell contact-dependent 413 
mechanisms might be required for these effects, e.g. enabling BMP7 processing. 414 
Freshly isolated human LCs were shown to lack detectable TLR4 and to express low or 415 
undetectable TLR5 and TLR2 (46,62,63). Van der Aar et al. (63) previously showed that these 416 
bacterial recognition receptors are repressed upon TGF-β1 stimulation of monocytes undergoing 417 
moLC differentiation and that dermal DCs express these TLRs. Consistently, we here showed that 418 
TGF-β1-LCs lack detectable TLR4, TLR5 and TLR2. Moreover, in vitro generated CD34+ cell-419 
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derived LCs in our study resembled x vivo isolated LCs in detectable expression of TLR1, TLR6 420 
(33,63) and TLR10 (33), as well as in low/non-detectable TLR7 and TLR8 (33). However, 421 
inconsistent data have been published regarded the expr ssion of TLR7/9/10 by ex vivo isolated LCs 422 
(33,62,63). Notably, while TLR3 is expressed by LCs and moLCs (63), we failed to detect TLR3 in 423 
CD34+ cell-derived LCs. Whether these differences are inherent to the specific culture models studied 424 
remains to be analyzed. We showed here using flow cytometry that BMP7-LCs are TLR2+, whereas 425 
TGF-β1-LCs lack detectable TLR2. Moreover, TGF-β1 LCs exceeded BMP7-LCs in levels of 426 
TLR10mRNA expression. Interestingly, TLR10 is regarded as the only known inhibitory receptor 427 
within the TLR family (recently reviewed in: (64)). TLR10 is able to homodimerize and 428 
heterodimerize with TLR1 and TLR2. Elevated TLR2 and diminished TLR10, observed in BMP7-LCs 429 
relative to TGF-β1-LCs, might thus contribute to the here observed more potent cytokine production 430 
of the former in response to PGN stimulation. It will be interesting to further analyze whether TLR10 431 
is expressed by in vivo LCs and if so, whether lesional psoriatic LCs exhibit diminished levels of 432 
TLR10. It is interesting to speculate that an inverse expression of TLR2/TLR10 might sensitize LCs 433 
from lesional psoriatic skin to gram positive bacteria such as Staphylococcus aureus. In line with this 434 
possibility, we detected substantial levels of TLR2 on LCs from lesional psoriatic skin. Consistently, 435 
PGN-stimulated BMP7-LCs produced higher levels of several inflammatory mediators (e.g.: IL6, 436 
TNFα, CXCL1, CCL3/4) relative to TGF-β1-LCs. Our observations are consistent with the 437 
demonstration that TLR2 stimulated LCs are potent inducers of Th17 polarization, highlighting the 438 
importance of TLR2 in immune responses in inflamed skin (65). Future studies are required to analyze 439 
in vitro generated LCs for additional cytokines such as IL-22 and IL-23 known to be involved in 440 
psoriasis. Moreover, intracellular cytokine staining eeds to be performed to determine the cellular 441 
origin of the cytokines measured in the supernatants of LC-T cells co-cultures. 442 
CD207+ BMP7-LCs phenotypically resemble LCs found in lesional psoriatic skin in that these 443 
cells are also CD1c+CD206+. Similarly, LCs generated in vitro from monocytes or from peripheral 444 
blood CD1c+ DCs express CD1c and CD206, consistent with the concept that these cells may develop 445 
into LCs during inflammation (reviewed in: (66)). A monocyte origination of LCs is also evident from 446 
studies on their development from CD34+ cells in vitro. Monocyte intermediates which arise in these 447 
cultures have to lose expression of the monocyte identity factor KLF4, in order to differentiate into 448 
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LCs (67). In conclusion, our data are consistent with a model whereby monocytes immigrate to the 449 
psoriatic epidermis and there differentiate into CD207+CD1a+CD1c+CD206+ LCs. It has been 450 
previously shown that in psoriasis CD206 is expressed by a subset of CD1a+ epidermal cells (37). 451 
Whether human inflammation-associated CD207+CD1c+CD206+ LC arise from myeloid progenitor 452 
cells, CD14+ monocytes or CD1c+ blood DC remains to be studied. In this context it is interesting to 453 
note that BMP7-LCs phenotypically differed from moDCs, previously shown to resemble atopic 454 
dermatitis-associated IDECs (36–39). 455 
Our results demonstrated, that in vitro BMP7-LCs express higher levels of several pro-456 
inflammatory genes and exhibit more potent T cell stimulatory capacity than TGF-β1-LCs. This is 457 
consistent with the observation that CD1a on LCs facilit tes psoriatic skin inflammation both in 458 
patients and the murine system (68). However, a regulatory function of these cells in vivo cannot be 459 
ruled out, considering previously demonstrated regulatory properties of semi-mature or even mature 460 
DCs (69); recently reviewed in: (70).  With regards to a possible function of psoriatic inflammation-461 
associated LCs, we previously showed that LCs are dispensable for the induction phase of psoriatic 462 
lesions in Junf/fJunBf/f K5cre-ERT mice; however they exerted an immune-regulatory function in 463 
chronic lesions (7). Despite our here presented observations that murine lesions in these mice are also 464 
BMP7hi/p-SMAD1/5/8hi, a direct translation of these findings to the human system must take into 465 
account major species differences; recently reviewed in: (70). 466 
We showed that TGF-β1 stimulation represses CD1c and CD206 expression in LCs generated 467 
in response to BMP7. It will be interesting to perform therapy-oriented in vivo studies addressing 468 
whether bone marrow-derived psoriatic LCs might differentiate further into steady-state-like LCs 469 
during the resolution phase of cutaneous psoriatic lesions, and whether this process is driven or can be 470 
augmented by TGF-β ALK5 signaling. Moreover, future studies are required to address the molecular 471 
mechanism of enhanced BMP7 expression in psoriatic lesions. Among several factors, high BMP7 472 
levels throughout the epidermal psoriatic lesions might be due to the expansion of basal keratinocytes 473 
or enhanced processing of BMP7 precursor molecules. 474 
In conclusion, our data indicate that available TGF-β family members within psoriatic 475 
epidermal lesions preferentially activate the BMP signaling cascade, leading to the generation of 476 
18 
 
proliferative, inflammation-associated LCs. Therapeutically targeting of this pathway, or restoration f 477 
canonical TGF-β signaling, might allow for interfering with cutaneous psoriatic lesion formation.  478 
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Figure legends 731 
 
Fig. 1. BMP7-driven LCs show up-regulation of inflammation-associated genes.  
(A) Schematic overview of in vitro LC generation from CD34+ cord blood hematopoietic progenitor 
cells. Bright field images represent day 7 LC clusters. Flow cytometry contour plots represent day  
7 expression of CD1a/CD207 induced by TGF-β1 or BMP7. (B) Heat map visualizes gene expression 
profiles of differentially expressed genes. CD1a+/CD207+ LCs were generated from three independent 
donors in response to TGF-β1 or BMP7 and were FACS sorted before analysis. Colors represent high 
(red) and low (blue) intensity. (C) qRT-PCR analysis of TLR1-10 mRNA expression by day 7 
generated MACS sorted LCs (TGF-β1 vs. BMP7). Values are normalized to HPRT (n=4, ±SD, 2-
tailed Student’s t test, *P<0.05; ** P<0.005). (D) Flow cytometry contour plots represent day 7 
expression of TLR2 on CD207+LCs induced by TGF-β1 or BMP7. Graph represents mean 
fluorescence intensity (MFI) of TLR2 by CD207+ cells (n=4, ±SD, 2-tailed Student’s t test, *P<0.05)  
(E) MACS sorted LCs (TGF-β1-LCs or BMP7-LCs) were activated or not for 48h with 5µg/ml PGN 
and cytokine production was measured by cytokine array (right; n=3, 1-way ANOVA, corrected with 
Tukey multiple comparison test, * P<0.05; ** P<0.005; *** P<0.005).  
 
Fig. 2. Immunophenotypic analysis of in vitro generated LCs. 
(A) Pre-expanded CD34+ cells were cultivated for 7 days with GM-CSF, FLT3-L, SCF, TNFα and 
either TGF-β1 or BMP7. Histograms depict relative expression level of indicated markers for gated 
CD1a+/CD207+ cells. Bars graphs represent mean fluorescence intensity (MFI) for listed markers 
(n=4, mean ±SD, 2-tailed Student’s  test, * P<0.05; ** P<0.005; *** P<0.0005). (B) Phenotype of 
MACS sorted peripheral blood monocytes vs. CD1c+ DCs. (C) CD14+ peripheral blood monocytes 
were differentiated to LCs for 5 days with GM-CSF and either TGF-β1 or BMP7. Histograms depict 
relative expression level of CD1c and CD206 for gated CD1a+/CD207+ cells (n=3). (D) CD1c+ 
peripheral blood DCs were differentiated to LCs for 3 days with GM-CSF and either TGF-β1 or 
BMP7. Histograms depict relative expression level of CD1c and CD206 for gated CD1a+/CD207+ 
cells (n=3). (E) CD34+ cells-derived LCs were FACS sorted for CD207+ cells, then fixed with 
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glutaraldehyde. Ultrathin sections were analyzed with Tecnai-20 transmission electron microscope 
(n=3). Size bars left = 2µm; right = 500nm. 
 
Fig. 3. The psoriatic epidermis harbours LCs with phenotypical resemblance to in vitro BMP7-
driven LCs. Representative images of sections from healthy adult human skin (A) and psoriatic 
lesions (B) were analyzed for the expression of CD207, CD1c and CD206. Arrow heads indicate triple 
positive CD207/CD1c/CD206 cells. Scatter plot (right) shows % of CD1c+CD206+ cells in CD207+ 
population (n=3, 2-tailed Student’s t test, *P<0.05). (C) Single cell suspension from biopsies of 
lesional skin of two psoriatic patients was analyzed with flow cytometry. After gating for singlets and 
viable cells, CD207+ cell population has been assessed for the expression of CD1c, CD206, and TLR2. 
Scatter plot (right) shows % of CD1c+CD206+TLR2+ cells in CD207+ population (n=2). 
Representative images of sections from healthy adult human skin (D) and psoriatic lesions (E) were 
analyzed for the expression of BMPRII and CD207. Scatter plot (right) shows % CD207+ co-
expressing BMPRII (n=3). Nuclei were visualized with Dapi. The dotted lines represent the dermal–
epidermal junction (n=3). Size bar=50µm. 
 
Fig. 4. BMP7-SMAD1/5/8 signaling is strongly induced in the psoriatic epidermis. Representative 
images of paraffin sections from healthy adult human skin and psoriatic lesions were analysed for the 
expression of CD1a, BMP7 (A, B) and CD1a, phospho-SMAD1/5/8 (pSMAD1/5/8) (C, D). Nuclei 
were visualized with Dapi. The dotted lines represent the dermal–epidermal junction (n=3). Size bar  
= 50µm. (E) Representative images of sections from the ears of Junf/fJunBf/f K5cre-ERT mice (ctrl – 
cre- litermate control, KO d7 – Jun/JunB knockout day 7, KO d12 – Jun/JunB knockout day 14) 
analysed for the expression of BMP7, CD207 and phos-SMAD1/5/8 (pSmad1/5/8). Nuclei were 
visualized with Dapi. The dotted lines represent the dermal–epidermal junction (n=5). (F) Schematic 
presentation of noggin (nog) and tamoxifen (Tx) treatment regiment of Junf/fJunBf/f K5cre-
ERT mice. (G) Ear swelling in control and Jun/JunB KO animals intradermaly injected with ctrl (0.1% 
BSA+beads) or noggin (nog+beads) n=5, ±SEM, 1-way ANOVA, corrected with Tukey multiple 
comparison test, * P<0.05. (H) Representative images of disease progression in nog (KO nog) and ctrl 
(KO ctrl) injected ears on experiment day 12. (I) Epidermal thickness in all experimental groups 
29 
 
assessed based on H&E staining (n=6, ±SEM, 1-way ANOVA, corrected with Tukey multiple 
comparison test, * P<0.05; ** P<0.005). (J) Ear skin histology (H&E, day 12) of control and Jun/JunB 
KO animals intradermally injected with ctrl (0.1% BSA) or noggin (nog). Size bar = 100µm 
 
Fig. 5. BMP7 supplementation is associated with mitotic activity of CD207
+
LC. 
(A) Pre-expanded CD34+ cells were cultivated for 7 days with GM-CSF, FLT3-L, SCF, TNFα and 
either TGF-β1 or BMP7. Graph depicts proliferation (total cell number) at day 7 and day 14 (n=4, 
mean ±SD, 2-tailed Student’s t test, ** P<0.005). (B) Graph represents % of phenotypically defined 
cells generated as stated in A, and analyzed by flow cytometry for the expression of LC lineage 
markers CD1a, CD207, CD324 (n=4, 2-tailed Student’s t test, * P<0.05; ** P<0.005). (C) 
Immunofluorescent and immunohistochemical stainings represent sections of day 7 generated LC 
clusters analyzed for the expression of Ki67 and CD207. Size bar = 50µm (n=3). (D)  % of Ki67+ cells 
among total CD207+ LCs. Each symbol represent one cluster (n=10, 2-tailed Student’s t test, **** 
P<0.0001). (E) Representative images of sections from healthy adult human skin and psoriatic lesions 
were analyzed for the expression of BMP7, Ki67 and CD207. Nuclei were visualized with Dapi. The 
dotted lines represent the dermal–epidermal junctio. Size bar = 50µm (n=3). (F) % of Ki67+ LCs 
calculated from immunohistology sections from healthy and psoriatic skin. Each symbol represents 
one patient. (G) Pie charts depict % of CD207+ cells confined to the KC layers expressing BMP7 in 
healthy (n=2, mean) and psoriatic skin (n=4, mean). Mean was calculated from immunohistological 
sections.  
 
Fig. 6. TGF-β1 represses BMP7-driven CD206+CD1c+ LC characteristics via ALK5.  
(A) Schematic representation of canonical TGF-β/BMP7 downstream signaling. (B) CD34+
 
cells were induced to differentiate into LCs in thepr sence of TGF-β1 or BMP7 for 8 days. Parallel 
day 6 cultures were supplemented with BMP7 or TGF-β1 as indicated. Representative contour plots 
show expression of CD1c vs CD206 by gated day 8 generated CD1a+CD207+ cells. Bars represent 
mean fluorescence intensity (MFI) of CD1c/CD206 for gated CD1a+/CD207+ cells (n=3, ±SD). (C) 
CD34+ cells were cultured for 4 days, then pre-treated or not with SB421543 (ALK5 inhibitor) for 1 h, 
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followed by TGF-β1 addition. Representative contour plots show day 7 generated gated 
CD1a+CD207+ cells analyzed for the expression of CD1c and CD206. Bars represent mean 
fluorescence intensity (MIF) of CD1c/CD206 expression by gated CD1a+/CD207+ cells pretreated or 
not with 8µM ALK5 inhibitor (n=3, ±SEM, 2-tailed Student’s t test, * P<0.05; ** P<0.005). 
 
Fig. 7. Reduction in lesional epidermal BMP7 expression in psoriasis correlates with clinical 
improvement. (A) Graph indicates relative staining intensity of BMP7 before and after dithranol 
treatment analyzed using ImageJ software (n=6, 2-tailed Student’s t test, * P<0.05). Representative 
images of sections from the lesional skin of psoriatic patients analyzed for the BMP7 expression 
before and after dithranol treatment. Size bar = 50µm. (B)  Correlation between PASI score reduction 
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Supplementary figure legends 52 
 53 
Fig. S1. BMP7-generated LCs exhibit immunostimulatory capacity.  54 
(A)105 naïve CD4 T cells were stimulated with the indicated numbers of LCs. Proliferation of T cells 55 
was monitored on day 5 of co-culture by addition of [methyl-3H]TdR, followed by measurement of 56 
[methyl-3H]TdR incorporation 18h later (n=3, ±SD, 2-tailed Student’s t test, *** P<0.0005). (B) 57 
Allogeneic, naive CD4+ T-cells were co-cultured for 5 days with TGF-β1  or BMP7-LCs. Cytokines in 58 
the supernatants were measured by Luminex system (n=6, ±SEM, 2-tailed Student’s t test P<0.05; ** 59 
P<0.005; *** P<0.0005). 60 
 61 
Fig. S2. BMP7-LCs express higher levels of pSmad1/5/8 than TGF-β1-LCs. 62 
Day 7 TGF-β1- and BMP7-LCs were MACS sorted. Cytospins were immunolabeled to asses CD207+ 63 
cells for the expression of pSMAD1/5/8. Graph indicates relative staining intensity of pSmad1/5/8 64 
analyzed using ImageJ software. For the relative fluorescence intensity 150 CD207+ cells/condition 65 
were measured (n=3, 2-tailed Student’s t test, **** P<0.0001). 66 
 67 
Fig. S3. BMP7-LCs have a unique phenotype distinct from moDCs. CD14
+
 peripheral blood 68 
monocytes were differentiated for 7 days with GM-CSF and IL-4 to moDCs. Histograms depict 69 




 cell population (n=4). 70 
 71 
Fig. S4. Inhibition of BMP signaling with noggin or Alk3 inhibitor results in decreased ear 72 
swelling in vivo. (A) Representative images of sections from the ears of Junf/fJunBf/f K5cre-ERT knock 73 
out mice injected intradermally (day 0) with beads-sorbed noggin (KO nog) or 0.1% BSA + beads 74 
control (KO ctrl). Samples were analyzed for the expr ssion of phospho-Smad1/5/8 (pSmad1/5/8) on 75 
day 12 of the experiment. Nuclei were visualized with Dapi. The dotted lines represent the dermal–76 
epidermal junction (n=3). (B) Junf/fJunBf/f K5cre-ERT knock out mice were treated topically from day 77 
10 of the experiment, with 10uM dorsomorphin (Dorso) f r 5 consecutive days. Graph represents 78 
differences in ear thickness measured on day 15 (n=-6, 2-tailed Student’s t test, **P<0.005).   79 
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Fig. S5. Hypothetical model of pathogenic epidermal BMP signaling in psoriasis.  80 
BMP7 is expressed aberrantly throughout all KC layers in the lesional psoriatic epidermis and 81 
promotes the generation of proliferative CD206+CD1c+TLR2+LCs from precursors. These psoriatic 82 
LCs occur scattered throughout the enlarged epidermis. Conversely, in the healthy epidermis, LCs are 83 
CD206-TLR2-CD1clow/-, exhibit a predominant basal/suprabasal location, a d the occasionally 84 
observed mitotic LCs are confined to the basal BMP7+ KC layer. In psoriasis, aberrantly activated 85 
canonical BMP-pSMAD1/5/8 signaling promotes lesion f rmation and induces the generation of 86 
inflammatory LCs, sensitized for bacterial signaling. Our data suggest that aberrant high BMP7 in 87 
psoriatic KCs is mediated by a KC intrinsic process and enhances microbial signals in psoriatic 88 





















Supplementary methods 108 
 109 
Cell isolation 110 
CD34+ hematopoietic progenitor/stem cells (HSCs): . Cord blood was collected during healthy, full-111 
term deliveries. Ethics approval (26-520) was obtained from the Medical University of Graz 112 
Institutional Review Board for these studies. Informed consent was provided to patients in accordance 113 
with the Declaration of Helsinki. Cord blood CD34+ HSCs were positively selected with magnetic 114 
sorting (EasySepTM Human CD34 Positive Selection Kit, StemCell TechnologiesTM). CD14+ 115 
monocytes, naive CD4+ T-cells, CD1c+ blood DCs: Buffy coats from healthy donors were purchased 116 
from Transfusion Medicine Department, Medical University of Graz, Austria. For the isolation of 117 
peripheral blood mononuclear cells (PBMCs) heparinized blood was separated by gradient 118 
centrifugation with LymphoprepTM (Axis Shield, Norway). Subsequently, various cells were isolated 119 
using magnetic sorting technique according to the manufacturer’s instructions. First, CD14+ monocytes 120 
were positively selected (CD14 MicroBeads, human, Miltenyi Biotec, Germany). Second, after 121 
depletion of CD19+ cells, CD1c+ blood dendritic cells were positively selected (CD1c+/BDCA-1 122 
Dendritic Cell Isolation Kit, human, Miltenyi Biotec, Germany). Last, naïve CD4+ T-cells were 123 
negatively selected (MagniSort™ Human CD4 Naïve T cell Enrichment Kit, ThermoFisher Scientific, 124 
USA). Purity of sorted cells was assessed by flow cytometry and was greater than 95%. 125 
 126 
Preparation of single cell suspension from psoriatic skin biopsies 127 
Punch biopsies (4 mm) have been taken from lesional skin of psoriatic patients. Ethics approval 128 
(EK700/2009) was obtained from the Medical University of Vienna Institutional Review Board for 129 
these studies. Informed consent was provided to patients in accordance with the Declaration of 130 
Helsinki. To prepare single cell suspension gentleMACSTM Dissociator (Miltenyi Biotec, Germany) 131 
have been used. Skin biopsy was cut into small pieces and transferred into gentleMACS C Tube 132 
(Miltenyi Biotec, Germany) containing mix of 900 µlCollagenase IV (0.5 Wünsch units/ml) and 100 133 
µl DNAse I (10 mg/ml). Tissue with enzymes was incubated overnight in 37°C in shaking water bath. 134 
This was followed by tissue disassociation using gentleMACSTM Dissociator system. Obtained cell 135 
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suspension was filtered through 100 µm cell straine a d centrifuged for 10 min in 4°C at 1600 rpm. 136 
After supernatant was discarded cell pellet was stained for flow cytometry analysis.   137 
 138 
Gene expression analysis 139 
The raw data of the dataset GSE49085 (1) (6 samples, Affymetrix Human Genome U133 Plus 2.0 140 
Array) was downloaded from Gene Expression Omnibus (2) and analysed in  141 
R 3.5.1 (https://www.R-project.org). The R package 'oligo' (3) was used for quality control and 142 
pre-processing. The R package 'limma' (4) was used to calculate log2 (fold changes) and p values 143 
between the groups with patients as covariates. Specific filtering was applied using selected 144 
features associated with dendritic cells (24). The p-values were adjusted for multiple testing with 145 
Benjamini and Hochberg’s method to control the false discovery rate. Genes with an absolute 146 
log2(fold change) > log2(1.5) and an adjusted p-value <= 0.05 were considered as differentially 147 
expressed. Hierarchical clustering with Euclidean distance and Ward linkage was performed and 148 
visualized as a heatmap. The heatmap was generated using the R package 'gplots'.  149 
 150 
RNA isolation, reverse transcription (RT-PCR) and real-time quantitative PCR (qPCR) 151 
Prior to the RNA extraction, day 7 CD207+ cells were isolated with magnetic sorting (human 152 
CD207/Langerin MicroBeads, Miltenyi Biotec, Germany). Extraction of total RNA from sorted LCs 153 
(purity ≥ 80%) was performed with RNeasy Micro Kit (Qiagen, Germany). cDNA was generated 154 
using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA). The qPCR was 155 
performed using Fast SYBR™ Green Master Mix (Applied Biosystems, USA) and CFX96 Real-Time 156 
Thermal cycler (Bio-Rad Laboratories, USA). All steps were performed according to the 157 
manufacturer’s instructions. Values were normalized to HPRT. Primer sequences are listed in the 158 
supplementary table 2.  159 
 160 
Cytokine measurements  161 
Day 7 CD207+ LCs (TGF-β1-LCs vs. BMP7-LCs) were MACS sorted (purity ≥90%) and activated 162 
with 5 µg/ml PGN. After 48h supernatants were collected. The proteome profiler human cytokine 163 
array kit (R&D Systems, USA) was used according to the manufacturer’s instructions. Spot intensity 164 
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was quantified with ImageLabTM software (BioRad). For the quantitative measurement of cytokines in 165 
the supernatants from T-cell/LC co-culture experiments Luminex system was used. 166 
 167 
Transmission electron microscopy (TEM) 168 
Day 7 FACS sorted CD207+ LCs were fixed with 2,5% Glutaraldehyde and 1% OsO4 palade and 169 
dehydrated in a graded ethanol series. Afterward, LCs were embedded in Epon (Serva, Germany) and 170 
ultrathin sections (70–100 nm) were cut using an UltraCut-UCT ultramicrotome (Leica Inc., Austria), 171 
transferred to copper grids, and viewed either unstai ed or stained with 1% uranyl acetate and 5% lead 172 
citrate (Merck, Germany) using a Tecnai-20 TEM (Tecnai-20 equipped with a LaB6 cathode; FEI 173 
Company, Netherlands) at an acceleration voltage of 80 kV. Digital images were recorded with an 174 
Eagle 4 k-CCD camera; chip size: 4,096 × 4,096 pixels (FEI Company). 175 
 176 
Immunofluorescence and immunohistochemistry 177 
Healthy, adult (18-42 year) skin samples were colleted after plastic surgery. Ethics approval (27-071) 178 
was obtained from the Medical University of Graz Institutional Review Board for these studies. 179 
Informed consent was provided to patients in accordance with the Declaration of Helsinki. Paraffin 180 
sections (4µm) were subjected to HIER antigen retrieval in Target Retrieval Solution pH 6.0 181 
(Agilent/Dako, USA) followed by blocking with 5% donkey serum (Jackson ImmunoResearch 182 
Laboratories, USA). Primary and secondary antibodies are listed in the supplementary table 4. 183 
Staining specificity controls were performed with sub titution of primary antibodies by isotype-184 
matched control antibody against irrelevant antigens followed by corresponding secondary antibody. 185 
To visualize nuclei, sections were counterstained with 10µg/mL DAPI. Images were obtained with 186 
Leica DM4000B microscope and ZEIS LSM700 confocal microscope and processed using LAS V3.8, 187 
ZEN 2.3 lite, and ImageJ software.  188 
 189 
Mice 190 
 Junf/fJunBf/f K5cre-ERT mice (mixed background) with conditional deletion f Jun/JunB under keratin 191 
5 promoter (K5cre-ERT) were described previously (5). To delete Jun/JunB K5-creER positive (KO) or 192 
negative (ctrl; Junf/fJunBf/f) mice were injected intraperitoneally with 1 mg tamoxifen (Tx, Sigma-193 
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Aldrich, USA) in an emulsion with sunflower seed oil (Sigma-Aldrich)/ethanol mixture (10:1) on 5 194 
consecutive days. Deletion of Jun/JunB was verified by PCR. Mice were kept in the animal facility of 195 
the Medical University of Vienna in accordance with institutional policies and federal guidelines. 196 
Animal experiments were approved by the Animal Experim ntal Ethics Committee of the Medical 197 
University of Vienna and the Austrian Federal Ministry of Science and Research. (Animal license 198 
numbers: GZ 66.009/124-BrGT/2003; GZ 66.009/109-BrGT/2003; BMWF-66.009/0073-II/10b/2010 199 
BMWF-66.009/0074-II/10b/2010; BMWFW-66.009/0200-WF/II/3b/2014; and BMWF W-200 
66.009/0199-WF/II/3b/2014). 201 
 202 
Intradermal noggin injections in mice 203 
For delivery of Noggin-adsorbed beads, we used a previously described approach (6–9). Ears of 204 
Junf/fJunBf/f K5cre-ERT mice were injected intradermally one time with a mix of FluoSpheres® 205 
(Invitrogen, USA) and noggin (300ng) 24h before Tx injection. For control challenge injection a mix 206 
of FluoSpheres® and 0.1% BSA was used.  207 
 208 
Topical treatment with dorsomorphin 209 
Junf/f/JunBf/fK5-cre-ERT mice aged 5-6 weeks were injected with Tamoxifen (Tx) to trigger psoriasis 210 
as previously published (5,10) After five consecutive days of Tx injection, mice were given an 211 
additional 5 days to manifest a pronounced phenotype. After this, for another five consecutive days 212 
inhibitors were applied topically to the ears of the mice. Dorsomorphin (Tocris Bioscience, UK) was 213 
diluted to a concentration of 10µM in DMSO; of this mixture, 40µL were pipetted onto each mouse 214 
ear (20µl to the dorsal, 20µl to the ventral side). The control group received pure DMSO. Ear 215 
thickness was measured daily via caliper. After five days of treatment (from day 10 to 15), the increase 216 
of ear thickness relative to ear thickness at the start of inhibitor treatment was calculated. 217 
 218 
Murine skin thickness measurement 219 
Paraffin sections from mouse ears were stained with hematoxylin and eosin (Sigma, USA). Images 220 
were obtained with Olympus BX53 (Olympus) microscope. Epidermal thickness was measured in 20 221 
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random fields on 5 independent pictures per sample (magnification 10x) using AxioVision LE64 222 
software (Zeiss). 223 
 224 
T-cell proliferation assay (MLR) 225 
The assay was performed as described previously (11). In brief, MACS-sorted CD207+ LCs were 226 
seeded in graded numbers with a constant number (5x105) of purified, allogenic naive CD4+ T-cells in 227 
96-well tissue culture plates in RPMI-1640 medium (Sigma-Aldrich, USA) supplemented with 10% 228 
FBS. The proliferation of T-cells was analyzed on day 5 of culture by adding [methyl-3H]TdR 229 
followed by incorporation measurement [methyl-3H]TdR 18h later. Incorporated radioactivity was 230 
measured using a 1450 microbeta plate reader (Wallac-Trilux Instrument; Life Science). Supernatants 231 
were collected for cytokine measurement (Luminex) before adding [methyl-3H]TdR. Assays were 232 




















Supplementary tables 251 
 252 
Antibody (anti-) Clone Company 
CD1a HI149 BD Biosciences 
CD1b SN13(K5-1B8) BioLegend 
CD1c 510/21A3 BD Biosciences 
CD11b ICRF44 BioLegend 
CD11c BU15 BioLegend 
CD14 M5E3 BioLegend 
CD31 WM59 BioLegend 
CD36 CB38 BD Biosciences 
CD40 5C3 BD Biosciences 
CD80 L307.4 BD Biosciences 
CD86 2331(FUN-1) BD Biosciences 
CD206 15-2 BioLegend 
CD207 DCGM4 Beckman Coulter 
CD209 eB-h209 eBioscience 
CD324/E-cadherin 67A4 BD Biosciences 
CXCR1 8F1-CXCR1 BioLegend 
CX3CR1 2A9-1 eBioscience 
HLADR G46-6 BD Biosciences 
EpCAM/Trop1 EBA-1 BD Biosciences 
Trop2 162-46 BD Biosciences 
TLR2 1167 BD Biosciences 
 253 

















Stem cell factor (SCF) 
Fms-related tyrosine kinase 3 ligand (FLT3-L) 
Tumor necrosis factor alpha (TNFα) 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) 
Interleukin 4 (IL-4) 
Transforming growth factor beta 1 (TGF-β1) R&D Systems, 
USA Recombinant mouse noggin (NOG) 
Bone morphogenetic protein 7 (BMP7) 
ImmunoTools, 
Germany 
Alk4/5/7 inhibitor (SB431542) Tocris 
Bioscience, UK Dorsomorphin 
FluoSpheres® carboxylate-modified microspheres 0.2 µm, crimson fluorescent 
(625/645) 2% solids 
Invitrogen, USA 
Recombinant extracellular domain of Notch ligand Delta-1 (Delta-1ext–IgG) 
Kindly provided 
by I. Bernstein 
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pAb – polyclonal antibody 298 
mAb – monoclonal antibody  299 
 300 
Primary antibody Clone Company 
pAb rabbit anti-CD207 N/A Sigma-Aldrich, USA 
mAb rat anti-CD207 Alexa Fluor-488 929F3.01 Dendritics, France 
pAb rabbit anti-BMP7 N/A LifeSpan BioSciences, USA 
mAb mouse anti-Ki67 MIB-1 Dako, USA 
pAb rabbit anti-pSMAD1/5/8 N/A CellSignaling, USA 
mAb mouse anti-CD1a O10 Novus Biologicals, USA 
mAb mouse anti-CD1c OTI2F4 Abcam, UK 
pAb rabbit anti-CD206 N/A 
Sigma-Aldrich, USA 
pAb rabbit anti-BMPR2 N/A 
 
   Secondary antibody (conjugated) 
pAb donkey anti-mouse DyLight488 N/A 
Jackson ImmunoResearch 
Laboratories, USA 
pAb donkey anti-mouse Cy3 N/A 
donkey anti-rabbit Cy3 N/A 
donkey anti-rabbit DyLight488 N/A 
donkey anti-rabbit Alexa Fluor-647 N/A 
 301 
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